T2 Biosystems, Inc. (NASDAQ:TTOO) Sees Large Growth in Short Interest

T2 Biosystems, Inc. (NASDAQ:TTOOGet Free Report) was the target of a large growth in short interest in the month of November. As of November 15th, there was short interest totalling 1,020,000 shares, a growth of 22.2% from the October 31st total of 834,800 shares. Approximately 14.7% of the company’s stock are sold short. Based on an average daily volume of 581,500 shares, the days-to-cover ratio is presently 1.8 days.

Analysts Set New Price Targets

Separately, StockNews.com began coverage on T2 Biosystems in a research note on Monday, November 25th. They issued a “sell” rating on the stock.

View Our Latest Stock Report on T2 Biosystems

T2 Biosystems Trading Up 14.9 %

NASDAQ TTOO traded up $0.07 during trading on Friday, hitting $0.57. The stock had a trading volume of 1,976,148 shares, compared to its average volume of 363,966. The company’s 50-day moving average price is $1.14 and its two-hundred day moving average price is $3.28. T2 Biosystems has a 12 month low of $0.42 and a 12 month high of $8.38.

Institutional Investors Weigh In On T2 Biosystems

A hedge fund recently raised its stake in T2 Biosystems stock. Virtu Financial LLC boosted its holdings in T2 Biosystems, Inc. (NASDAQ:TTOOFree Report) by 29.9% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 13,096 shares of the medical equipment provider’s stock after acquiring an additional 3,018 shares during the period. Virtu Financial LLC owned 0.24% of T2 Biosystems worth $39,000 as of its most recent filing with the Securities and Exchange Commission. 23.18% of the stock is currently owned by institutional investors.

T2 Biosystems Company Profile

(Get Free Report)

T2 Biosystems, Inc, an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine.

Featured Stories

Receive News & Ratings for T2 Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.